23:03 , Mar 8, 2019 |  BC Extra  |  Company News

Merck partners with King’s College to develop non-opioid pain therapies

Merck has partnered with King's College London to translate research elucidating HCN2 as a pain target to develop non-opioid treatments for chronic neuropathic pain. The deal builds on work from the lab of Peter McNaughton...
21:29 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting HCN2 could help treat pain in diabetic neuropathy. In a mouse model of diabetic neuropathy, the HCN channel inhibitor Corlanor ivabradine or nociceptive neuron-specific knockout of HCN2 decreased mechanical...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2) Mouse studies suggest increasing hyperpolarization-activated current in dopaminergic neurons in the brain's ventral tegmental area (VTA)...
07:00 , Sep 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2) Mouse studies suggest inhibiting HCN2 could help treat inflammatory and neuropathic pain. In mice, a nonspecific...